Cite
Optimizing Antiviral Dosing for HSV and CMV Treatment in Immunocompromised Patients.
MLA
Huntjens, Daan W., et al. “Optimizing Antiviral Dosing for HSV and CMV Treatment in Immunocompromised Patients.” Pharmaceutics, vol. 15, no. 1, Jan. 2023. EBSCOhost, https://doi.org/10.3390/pharmaceutics15010163.
APA
Huntjens, D. W., Dijkstra, J. A., Verwiel, L. N., Slijkhuis, M., Elbers, P., Welkers, M. R. A., Veldkamp, A. I., Kuijvenhoven, M. A., de Leeuw, D. C., Abdullah-Koolmees, H., Kuipers, M. T., & Bartelink, I. H. (2023). Optimizing Antiviral Dosing for HSV and CMV Treatment in Immunocompromised Patients. Pharmaceutics, 15(1). https://doi.org/10.3390/pharmaceutics15010163
Chicago
Huntjens, Daan W, Jacob A Dijkstra, Lisanne N Verwiel, Mirjam Slijkhuis, Paul Elbers, Matthijs R A Welkers, Agnes I Veldkamp, et al. 2023. “Optimizing Antiviral Dosing for HSV and CMV Treatment in Immunocompromised Patients.” Pharmaceutics 15 (1). doi:10.3390/pharmaceutics15010163.